Pearl IRB first firm in state to pre-screen clinical drug trials
Two former Eli Lilly and Co. employees launched the firm that promises to attract more clinical trial business to the state.
Health Care & Life Sciences
Articles
Lilly gains panel’s backing to expand Cymbalta use
Outside advisers to the Food and Drug Administration voted 8-6 Thursday in favor of a broader use of Cymbalta on the basis
of studies in lower back pain and osteoarthritis of the knee.
Lilly wins temporary ban on sales of Strattera copies
The invalidation of Lilly’s Strattera patent opened the door for as many as 10 companies to sell generic versions of the drug,
which generated U.S. sales of $445.6 million last year as a treatment for attention deficit hyperactivity disorder.
Cancer drug developer Endocyte files for IPO
The company, headquartered at Purdue Research Park, said the number of shares to be offered and their price range have yet
to be determined.
Lilly Alzheimer’s drug prospect only the latest to fail
A dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the
disease since 1906, have failed in mid- to late-stage testing since 2003.
Bad news piles up for Lilly
What a tough week for Lilly. On Aug. 12, a judge struck down the Indianapolis-based drugmaker’s U.S. patent on Strattera,
which might cost the company about $450 million in annual revenue. Then, five days later, Lilly halted clinical trials on
one
of its experimental Alzheimer’s medicines, because patients did worse on the drug than on a placebo.
Q&A
Dr. Kevin Macadaeg, vice president of the Indiana Spine Group, talked about his physician
group's decision to build a 60,000-square-foot medical office and "bioskills" lab in Carmel next year, as well
as the group's commitment to grow independently in the face of pressures from hospital acquisitions and health reform.
Expanding hospitals target Bloomington
Monroe Hospital in Bloomington is the latest target in the statewide buildup by hospital systems. St. Vincent Health, St.
Francis and at least one other system have all had talks in the past month with Monroe.
Lilly’s Cymbalta helps chronic pain in U.S. review
Approval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta’s
annual sales.
Lilly halts development of Alzheimer’s drug
Studies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical
giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through
2014.
Medco to acquire United BioSource for $710M
Medco operates an automated pharmacy and distribution center in Whitestown in Boone County, and it plans to employ more than
1,400 people there by 2012.
Biomet investing $26M to expand, create nearly 280 jobs
Orthopedics giant Biomet Inc. plans to invest $26 million to grow operations in its hometown of Warsaw, adding 278 jobs by
the end of 2012.
Eli Lilly loses patent lawsuit for Strattera
Eli Lilly and Co. on Thursday lowered its revenue outlook for the year after it lost a patent lawsuit over its attention
deficit hyperactivity drug Strattera. The patent had been set to expire in May 2017. Lilly plans to appeal.
Lilly braces for plunge in profits
Indianapolis-based drugmaker Eli Lilly and Co. faces such an unprecedented string of patent expirations and an unheard-of
loss of revenue that it’s hard to picture what the company will look like in five years.
Bedsore preventer turns to detection
Changes in reimbursement could fuel market for WoundVision’s product.
WellPoint, other health insurers race to join accountable care groups
The health care industry is responding to reforms that will pay doctors bonuses if they provide high-quality care and save
Medicare money.
Indiana life sciences group moves ahead
INpact not-for-profit arranged virtual approach to help startup firm develop device to detect tooth cavities early.
Life sciences panel pegs bright spots in Indiana
Leaders tackle issues ranging from research to cold storage to the future of Eli Lilly and Co.
Roche hit with new breed of patent suit
Roche Diagnostics, a Swiss company that keeps its U.S. headquarters in Indianapolis, has been sued for marking its Accu-Chek
blood glucose monitors and accessories with patents that are expired. Illinois resident David O’Neill has sued on behalf
of the U.S. government to recover damages of $500 per infraction.
Arcadia sees smaller loss, extends WellPoint pact
Indianapolis-based health care firm reaches agreement to offer its DailyMed product to more WellPoint Inc. health plan members.